SCHEMBL14612909

SCHEMBL14612909

CCOC(=O)N1CCN(C(C)CC)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
POLB P06746 2/20 0.53
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
KDM4E B2RXH2 3/20 0.53
TSHR P16473 2/20 0.50
RECQL P46063 1/20 0.50
CASP6 P55212 1/20 0.50
GAA P10253 4/20 0.49
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
MAPT P10636 2/20 0.46
ABL1 P00519 1/20 0.46
RIN1 Q13671 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL681679 0.85 ALDH1A1 (0.56) ALDH1A1POLBHTTSMN1; SMN2KDM4E
SCHEMBL18500412 0.83 ALDH1A1 (0.55) ALDH1A1POLBHTTSMN1; SMN2KDM4E
SCHEMBL1684895 0.82
SCHEMBL10985089 0.82 ALDH1A1 (0.72) ALDH1A1POLBHTTSMN1; SMN2KDM4E
SCHEMBL4391742 0.81 USP2 (0.49) ALDH1A1HTTSMN1; SMN2KDM4ERECQL
SCHEMBL11571795 0.80 ALDH1A1 (0.45) ALDH1A1POLBHTTSMN1; SMN2KDM4E
SCHEMBL5958378 0.80 ALDH1A1 (0.47) ALDH1A1POLBHTTSMN1; SMN2KDM4E
SCHEMBL27789110 0.80 KDM4E (0.51) ALDH1A1POLBKDM4ERECQL
SCHEMBL28263285 0.79 KDM4E (0.54) ALDH1A1KDM4E
SCHEMBL10263815 0.79 PIK3CD (0.52) ALDH1A1SMN1; SMN2KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257515-B1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NAT RECH SCIENT (FR) 2017-05-17 EP disclosed
EP-2389372-B1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS INC (US) 2015-09-09 EP disclosed
EP-2565193-A1 Compositions and methods for inhibition of the JAK pathway Rigel Pharmaceuticals, Inc. (US) 2013-03-06 EP disclosed
US-20070043051-A1 Methods and compositions of novel triazine compounds TIMMER RICHARD T 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043051-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS ALDH1A1 4407/4885POLB 3147/4885HTT 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.